



PATENT  
2543-1-032

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Herath Mudiyanselage Athula Chandrasiri HERATH et al.

SERIAL NO.: 10/700,340

EXAMINER: Unassigned

DATE FILED: November 3, 2003

ART UNIT: Unassigned

FOR: PROTEINS, GENES AND THEIR USE FOR DIAGNOSIS AND  
TREATMENT OF BREAST CANCER

**CERTIFICATE OF MAILING UNDER 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA on November 24, 2003.

Karen Garipoli  
(Name of Depositor)

  
(Signature and Date)


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


**INFORMATION DISCLOSURE STATEMENT**

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References AA through CE listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,  
  
David A. Jackson  
Attorney for Applicants  
Registration No. 26,742

KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, New Jersey 07601  
(201) 487-5800



Sheet 1 of 1

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2543-1-032
		SERIAL NO.	10/700,340
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Herath, et al.
		FILING DATE	November 3, 2003
		GROUP	Unassigned

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	5,994,081	11/30/99	Tang et al.			

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO
	BA	WO 97/46884	12/11/97	PCT			
	BB	WO 99/32625	7/1/99	PCT			
	BC	WO 98/35229	8/13/98	PCT			
	BD	WO 98/22139	5/28/98	PCT			

#### OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Page, MJ, et al, Proteomics: a major new technology for the drug discovery process, DDT, Vol. 4, No. 2, (1999), Pgs. 55-62
CB	Lumachi,F, et al, Long-Term Follow-up Study in Breast Cancer Patients Using Serum Tumor Markers CEA and CA 15-3, Anticancer Research, 19: (1999), Pgs. 4485-4490
CC	Payne,R,et al, Automated Assay for HER-2/neu in Serum,Clinical Chem,(2000),Pgs 175-182
CD	Page,MJ,et al,Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties,PNAS, Vol 96,No.22,(1999), Pgs. 12589-12594
CE	Fowler,Jr,JE,etal,Predictors of First Repeat Biopsy Cancer Detection with Suspected Local Stage Prostate Cancer, The Jour. Of Urology, Vol.163,(2000), Pgs. 813-818
EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	